Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Poseidon Pharmaceuticals AS

Latest From Poseidon Pharmaceuticals AS

Are Spin-Outs Really a Better Bet?

Big Pharma spin-outs may on average have raised 50% more private money than non-spin-outs over the last five years, but it's not yet clear whether they always deliver better returns on investment. Still, spin-outs remain an investor favorite, and in Europe are becoming the mainstay of a sustainable biopharma industry.
BioPharmaceutical Strategy

In Search of NeuroSearch

Recent clinical failures have left Denmark's NeuroSearch uncomfortably dependent on NS2330, a promising phase II Alzheimer's and Parkinson's treatment out-licensed to Boehringer Ingelheim. To reduce risk, NeuroSearch will have to partner its remaining research programs earlier.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Parent & Subsidiaries
  • Poseidon Pharmaceuticals AS
  • Senior Management
  • Søren Peter Olesen, MD, PhD, Pres. & CEO
    Maria Belvisi, PhD, CSO
  • Contact Info
  • Poseidon Pharmaceuticals AS